Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.

Saved in:
Bibliographic Details
Title: Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
Authors: Aronne LJ; Comprehensive Weight Control Center, Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine, New York, NY, USA. ljaronne@med.cornell.edu., Horn DB; Center for Obesity Medicine and Metabolic Performance, Departments of Surgery and Internal Medicine, University of Texas McGovern Medical School, Houston, TX, USA., le Roux CW; Metabolic Medicine, School of Medicine, Conway Institute, University College Dublin, Dublin, Ireland.; Diabetes Research Centre, Ulster University, Coleraine, UK., Chao AM; Johns Hopkins School of Nursing, Baltimore, MD, USA., Ho W; Keck School of Medicine of University of Southern California, Los Angeles, CA, USA., Halpern B; Obesity Center, Nove de Julho Hospital, São Paulo, Brazil., Griffin R; Eli Lilly and Company, Indianapolis, IN, USA., Xie C; Eli Lilly and Company, Indianapolis, IN, USA., Valderas EG; Eli Lilly and Company, Indianapolis, IN, USA., Lee CJ; Eli Lilly and Company, Indianapolis, IN, USA., Ribeiro A; Eli Lilly and Company, Indianapolis, IN, USA., Hyman DM; Eli Lilly and Company, Indianapolis, IN, USA., Glass L; Eli Lilly and Company, Indianapolis, IN, USA., Xavier N; Eli Lilly and Company, Indianapolis, IN, USA.
Source: Nature medicine [Nat Med] 2026 May 13. Date of Electronic Publication: 2026 May 13.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1546-170X
DOI:10.1038/s41591-026-04386-7